MedTrace Logo

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

NCT04627428 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-10-15

No results posted yet for this study

Summary

The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.

Conditions

Interventions

BIOLOGICAL

RPESC-RPE-4W

RPESC-RPE-4W

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Eye Institute (NEI)

    collaborator NIH

  • Regenerative Research Foundation

    collaborator UNKNOWN

  • California Institute for Regenerative Medicine (CIRM)

    collaborator OTHER

  • Luxa Biotechnology, LLC

    lead INDUSTRY

Principal Investigators

  • Rajesh C Rao, M.D. · University of Michigan Kellogg Eye Center

  • Theodore Leng, MD, FACS · Spencer Center for Vision Research at Stanford University

  • David S Liao, MD, PhD · Retina-Vitreous Associates Medical Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-05
Primary Completion
2026-12-01
Completion
2026-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04627428 on ClinicalTrials.gov